Zobrazeno 1 - 10
of 68
pro vyhledávání: ''
Autor:
Ryusaku Matsumoto, Masaaki Yamamoto, Genzo Iguchi, Shin Urai, Hidenori Fukuoka, Wataru Ogawa, Kentaro Suda, Hiroki Shichi, Keitaro Kanie, Yutaka Takahashi, Hironori Bando, Yasunori Fujita
Publikováno v:
Cancer Immunology, Immunotherapy
Background Immune checkpoint inhibitors (ICIs) as a cancer immunotherapy have emerged as a treatment for multiple advanced cancer types. Because of enhanced immune responses, immune-related adverse events (irAEs), including endocrinopathies such as h
Autor:
Mette-Triin Purde, Rebekka Niederer, Nikolaus B. Wagner, Stefan Diem, Fiamma Berner, Omar Hasan Ali, Dorothea Hillmann, Irina Bergamin, Markus Joerger, Martin Risch, Christoph Niederhauser, Tobias L. Lenz, Martin Früh, Lorenz Risch, David Semela, Lukas Flatz
Publikováno v:
Purde, Mette‑Triin; Niederer, Rebekka; Wagner, ikolaus B.; Diem, Stefan; Berner, Fiamma; Hasan Ali, Omar; Hillmann, Dorothea; Bergamin, Irina; Joerger, Markus; Risch, Martin; Niederhauser, Christoph; Lenz, Tobias L.; Früh, Martin; Risch, Lorenz; Semela, David; Flatz, Lukas (2022). Presence of autoantibodies in serum does not impact the occurrence of immune checkpoint inhibitor-induced hepatitis in a prospective cohort of cancer patients. Journal of cancer research and clinical oncology, 148(3), pp. 647-656. Springer 10.1007/s00432-021-03870-6
Journal of Cancer Research and Clinical Oncology
Journal of Cancer Research and Clinical Oncology
Purpose Immune checkpoint inhibitor (ICI)-induced hepatitis belongs to the frequently occurring immune-related adverse events (irAEs), particularly with the combination therapy involving ipilimumab and nivolumab. However, predisposing factors predict
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::812bf92bad1e3210e93f155d71738545
https://boris.unibe.ch/162047/1/Purde2021_Article_PresenceOfAutoantibodiesInSeru.pdf
https://boris.unibe.ch/162047/1/Purde2021_Article_PresenceOfAutoantibodiesInSeru.pdf
Autor:
Yoshikazu Takahashi, Hidekazu Shirota, Takashi Yoshioka, Takuhiro Yamaguchi, Kota Ouchi, Michio Kuroki, Shin Takahashi, Masahiro Takahashi, Masaki Tanaka, Masanobu Takahashi, Chikashi Ishioka, Yasuhiro Sakamoto, Hideki Shimodaira, Hiroo Imai, Satoshi Kato, Keigo Komine, Kazunori Otsuka, Hiroyuki Shibata, Hisatsugu Ohori, Hiroaki Yamaguchi, Yasushi Tsuji
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose The current study aimed to determine the efficacy of trifluridine/tipiracil for elderly patients with advanced colorectal cancer. Methods This single-arm, open-label, multicenter, phase II study included elderly patients aged 65 years or more
Autor:
Hamid Abdollahi, Habib Zaidi, Mathieu Hatt, Arman Rahmim, Isaac Shiri, Ghasem Hajianfar, Mehrdad Oveisi, Hasan Maleki, Saeed Ashrafinia
Publikováno v:
Molecular Imaging and Biology, Vol. 22, No 4 (2020) pp. 1132-1148
Shiri, I, Maleki, H, Hajianfar, G, Abdollahi, H, Ashrafinia, S, Hatt, M, Zaidi, H, Oveisi, M & Rahmim, A 2020, ' Next-Generation Radiogenomics Sequencing for Prediction of EGFR and KRAS Mutation Status in NSCLC Patients Using Multimodal Imaging and Machine Learning Algorithms ', Molecular Imaging and Biology, vol. 22, no. 4, pp. 1132-1148 . https://doi.org/10.1007/s11307-020-01487-8
Molecular Imaging and Biology, 22(4), 1132-1148. SPRINGER
Shiri, I, Maleki, H, Hajianfar, G, Abdollahi, H, Ashrafinia, S, Hatt, M, Zaidi, H, Oveisi, M & Rahmim, A 2020, ' Next-Generation Radiogenomics Sequencing for Prediction of EGFR and KRAS Mutation Status in NSCLC Patients Using Multimodal Imaging and Machine Learning Algorithms ', Molecular Imaging and Biology, vol. 22, no. 4, pp. 1132-1148 . https://doi.org/10.1007/s11307-020-01487-8
Molecular Imaging and Biology, 22(4), 1132-1148. SPRINGER
Aim: In the present work, we aimed to evaluate a comprehensive radiomics framework that enabled prediction of EGFR and KRAS mutation status in NSCLC cancer patients based on PET and CT multi-modalities radiomic features and machine learning (ML) algo
Autor:
Monserrat Mangas, Flora López, Marc Diez, Juana María Cano, Alberto Carmona-Bayonas, Alfonso Martín Carnicero, Aitziber Gil-Negrete, Manuel Cánovas, Marcelo Garrido, Paula Cerdá, Paola Pimentel, Alicia Hurtado, Marta Martín Richard, Federico Longo, Carolina Hernández Pérez, Ana Montes, Rosario Vidal Tocino, Eva Martínez de Castro, Aranzazu Arias-Martinez, Javier Gallego, Mónica Granja, Laura Visa, Nieves Martinez Lago, Carles Pericay Pijaume, Natalia Castro Unanua, Avinash Ramchandani, Raquel Hernández, Ana Custodio, Tamara Sauri, Paula Jiménez-Fonseca, Gema Aguado, María Luisa Limón, Mariona Calvo, Aitor Azkarate
Publikováno v:
Scientia
Gastric Cancer
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
r-FISABIO. Repositorio Institucional de Producción Científica
r-FISABIO: Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
Gastric Cancer
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
r-FISABIO. Repositorio Institucional de Producción Científica
r-FISABIO: Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
Background The purpose of our study was to develop an online calculator to estimate the effect of docetaxel triplets (DPF) in first line of advanced gastric cancer (AGC), and to assess the external validity of docetaxel trials in individual patients.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::82837869875d5aad20b11f5093a89906
https://hdl.handle.net/11351/7737
https://hdl.handle.net/11351/7737
Autor:
Poodt, Ingrid G. M., Schipper, Robert-Jan, de Greef, Bianca T. A., Vugts, Guusje, Maaskant-Braat, Adriana J. G., Jansen, Frits H., Wyndaele, Dirk N. J., Voogd, Adri C., Nieuwenhuijzen, Grard A. P., Roumen, R. M. H., Luiten, E. J. T., Rutgers, E. J. T., Vrancken-Peeters, M. T. F. D., Bessems, M., Klaase, J. M., Muller, S., Francken, A. B., Van Dalen, T., Koopal, S. A., Vissers, Y. L. J., Smidt, M. L., Merkus, J. W. S., Contant, C. M. E., Veldman, P. H., Linthorst-Niers, E. M. H., van der Sijp, J. R., Guicherit, O. R., Koppert, L. B., Bosch, A. M., Strobbe, L. J. A., Schlooz-Vries, M. S., Arntz, I. E., van Essen, J. A., de Waard, J. W. D., Vrouenraets, B. C., van Ooijen, B., Smidt, Marjolein
Publikováno v:
Breast Cancer Research and Treatment, 175(2), 419-428. SPRINGER
Breast Cancer Research and Treatment, 175, 2, pp. 419-428
Breast Cancer Research and Treatment
Breast Cancer Research and Treatment, 175(2), 419-428. Springer, Cham
Breast Cancer Research and Treatment, 175(2), 419-428. Springer New York
Breast Cancer Research and Treatment, 175, 419-428
Breast Cancer Research and Treatment, 175, 2, pp. 419-428
Breast Cancer Research and Treatment
Breast Cancer Research and Treatment, 175(2), 419-428. Springer, Cham
Breast Cancer Research and Treatment, 175(2), 419-428. Springer New York
Breast Cancer Research and Treatment, 175, 419-428
Purpose In patients with ipsilateral breast tumor recurrence (IBTR), the detection of distant disease determines whether the intention of the treatment is curative or palliative. Therefore, adequate preoperative staging is imperative for optimal trea
Autor:
T. Jeroen N. Hiltermann, Jiacong Wei, Arja ter Elst, Pei Meng, Anthonie J. van der Wekken, Lennart Johansson, Mohamed Z. Alimohamed, Harry J.M. Groen, M. M. Terpstra, Anke van Rijk, Menno Tamminga, Klaas Kok, Rolof P G Gijtenbeek, Anke van den Berg, John W. G. van Putten, Jos A. Stigt, Frank J. G. Scherpen
Publikováno v:
Targeted Oncology
Targeted oncology. SPRINGER
Targeted oncology. SPRINGER
Background The clinical relevance of epidermal growth factor receptor (EGFR) copy number gain in patients with EGFR mutated advanced non-small cell lung cancer on first-line tyrosine kinase inhibitor treatment has not been fully elucidated. Objective
Autor:
Agustí Barnadas, Silvia M. Vidal, Margarita Majem, Leticia Alserawan, Mariona Riudavets, Carlos Zamora, Jorgina Serra, Andrés Barba, Javier Gavira, Pablo Gallardo, M. Angels Ortiz, Georgia Anguera, Lidia Perea, Ivana Sullivan
Publikováno v:
CANCER IMMUNOLOGY IMMUNOTHERAPY
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Background Anti-PD-(L)1 blocking agents can induce immune-related adverse events (irAEs), which can compromise treatment continuation. Since circulating leukocyte-platelet (PLT) complexes contribute to inflammatory and autoimmune diseases, we aimed t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6e09d11d6e57947dc938268b24327bc5
https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=5108
https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=5108
Autor:
Lukas Schollenberger, Christoph Thomssen, Slavomir Krajnak, Nadia Harbeck, Thomas Decker, Christian Ruckes, Tanja Fehm, Marcus Schmidt, Christian Rose
Publikováno v:
Journal of Cancer Research and Clinical Oncology
Purpose Metronomic chemotherapy (MCT) is an increasingly used treatment option in hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2−) advanced/metastatic breast cancer (MBC) after failure of endocrine-based the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d71e18d1f5a367f18fa6e6cf0e457306
Autor:
Ana Custodio, Carolina Hernández Pérez, Mónica Granja, Aitor Azkarate, Aitziber Gil-Negrete, Laura Visa, Manuel Cánovas, Carles Pericay Pijaume, Tamara Sauri, Patricia Morales del Burgo, Gema Aguado, Felipe Alvarez-Manceñido, Olbia Serra, Paula Jiménez-Fonseca, Nieves Martinez Lago, M. Luisa Limon, Maria Alsina, Alicia Hurtado, Aranzazu Arias-Martinez, Alfonso Martín Carnicero, Javier Gallego, Ana Montes, P. Reguera, Paola Pimentel, Juana María Cano, Rosario Vidal Tocino, Virginia Arrazubi, Alberto Carmona-Bayonas, Diego Cacho Lavin, Alba Martinez-Torron, Avinash Ramchandani, Marta Martín Richard, Raquel Hernández, Flora López
Publikováno v:
Gastric Cancer
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
r-FISABIO. Repositorio Institucional de Producción Científica
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
r-FISABIO. Repositorio Institucional de Producción Científica
Background Advanced esophageal adenocarcinoma (EAC) is generally treated similarly to advanced gastroesophageal junction (GEJ-AC) and gastric (GAC) adenocarcinomas, although GAC clinical trials rarely include EAC. This work sought to compare clinical
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eb6610ee161c1b474b11a4778f667108
https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=4917
https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=4917